No takes yet. Share an insight, caveat, or question.
Experiments using the kinase inhibitor FB849 show improved T cell function in endometrial and ovarian cancers, indicating potential for immunotherapy.
Park et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: